GlassScriptPhysician profile
Jeffrey L Gross
NPI 1770549180
$52,170.36
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $9,065 · 2021: $6,987 · 2022: $272.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15,301.29 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $11,294.61 | 2019-2020 | |
| Genentech USA, INC. | $11,154.50 | 2019-2021 | |
| Emd Serono, INC. | $6,227.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $6,151.85 | 2019-2021 | |
| Biogen, INC. | $484.98 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $196.37 | 2019 | |
| Ucb, INC. | $151.85 | 2019 | |
| Allergan, INC. | $136.57 | 2019 | |
| Adamas Pharmaceuticals, INC. | $98.10 | 2019 | |
| Eisai INC. | $83.39 | 2019 | |
| Acorda Therapeutics, INC | $81.76 | 2019 | |
| Acadia Pharmaceuticals INC | $81.05 | 2019 | |
| Akcea Therapeutics, INC. | $72.38 | 2019 | |
| Csl Behring | $72.13 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.42 | 2019 | |
| Lundbeck LLC | $54.36 | 2019 | |
| Genentech, INC. | $49.95 | 2021 | |
| Avanir Pharmaceuticals, INC. | $49.28 | 2019 | |
| Amneal Pharmaceuticals LLC | $46.21 | 2019 | |
| Boston Scientific Corporation | $44.94 | 2019 | |
| Alnylam Pharmaceuticals INC. | $43.29 | 2019 | |
| Assertio Therapeutics, INC. | $34.64 | 2019 | |
| Mdd US Operations, LLC | $26.44 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.58 | 2021 | |
| Ge Healthcare | $19.45 | 2019 | |
| Lilly USA, LLC | $18.02 | 2019 | |
| Promius Pharma LLC | $17.96 | 2019 | |
| Abbvie INC. | $17.70 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.59 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.06 | 2019 | |
| Merz North America, INC. | $12.82 | 2019 | |
| Tanabe Pharma America, INC. | $12.28 | 2019 | |
| Grifols USA, LLC | $10.97 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.